Core Viewpoint - The company reported a significant increase in revenue for Q1-Q3 2025, but net profit showed a decline, indicating mixed financial performance amidst growth in specific business segments [1][2]. Financial Performance - For Q1-Q3 2025, the company achieved revenue of 10.21 billion yuan, a year-on-year increase of 21.8%, while net profit was 809 million yuan, a year-on-year decrease of 23.8% [1]. - In Q3 2025, the company recorded revenue of 4.197 billion yuan, a quarter-on-quarter increase of 27.5% and a year-on-year increase of 27.2%. Net profit for the same period was 317 million yuan, a quarter-on-quarter increase of 5.7% but a year-on-year decrease of 16.4% [1]. Business Segments - The heated tobacco and electronic vaporization businesses both experienced growth in Q3 2025, contributing to the record quarterly revenue [1]. - The company supported strategic clients in launching new heated tobacco products globally, leading to a significant increase in product shipments [1]. - The company also enhanced its localized operations and marketing efforts, which helped expand its consumer base and market share [1]. Product Development - BAT announced the launch of the gloHilo product line in Japan, Italy, Poland, and Serbia, aiming to reach 50 million adult consumers of smoke-free products by 2030 [2]. - The gloHiloPlus is the first two-piece heated product from the glo brand, featuring advanced heating technology and a mobile app for personalized settings [2]. Regulatory Developments - TranspireBio, a subsidiary of the company, successfully submitted an ANDA for Breo Ellipta, which, if approved, would grant the company a 180-day market exclusivity in the U.S. [2]. - Breo Ellipta is projected to generate sales of 2.02 billion USD in the U.S. in 2024, highlighting the potential impact of this regulatory milestone on the company's market position [2]. Profit Forecast and Investment Outlook - The company is expected to see significant contributions from its HNB business starting in 2026, with adjusted net profit forecasts for 2025-2027 set at 1.392 billion, 2.023 billion, and 2.759 billion yuan respectively [3]. - The company maintains a "buy" rating based on its technological and market leadership advantages [3].

Investment Rating - The report maintains a "Buy" rating for the company, with a target price not specified [6]. Core Insights - The company reported a revenue of 60.13 billion yuan for the first half of 2025, representing an 18.3% year-on-year growth. Gross profit reached 22.44 billion yuan, up 16.6%, with a gross margin of 37.3%, slightly down by 0.5 percentage points. However, net profit decreased by 28.0% to 4.92 billion yuan, and adjusted net profit was 7.37 billion yuan, down 2.1% [1][5]. - The company's self-owned brand business, primarily from electronic vapor products and vapor beauty products, generated 12.74 billion yuan in revenue, a 14.1% increase, accounting for 21.2% of total revenue. The European market contributed 10.69 billion yuan, up 15.1%, while the U.S. market saw a decline of 6.7% to 1.74 billion yuan. Notably, the Chinese market surged by 2595.2% to 306.18 million yuan, driven by the sales of the vapor beauty product "Lan Zhi" [2][3]. - The company is experiencing a recovery in its vapor electronic cigarette business, supported by stricter regulations against non-compliant products in global markets. This regulatory environment is expected to sustain growth in both self-owned brand and enterprise client businesses [3][4]. Segment Summaries - **HNB Products**: The company successfully supported strategic clients in launching the high-end HNB product Hilo series, which will be launched nationwide in Japan in September 2025. The company is committed to ongoing R&D in HNB products to address user pain points [4]. - **Vapor Medical**: The subsidiary, Chuan Si Bio, is focused on developing leading generic drugs for asthma and COPD in the U.S. and Europe, with plans for further collaboration with international pharmaceutical companies [4]. - **Vapor Beauty**: The "Lan Zhi" home beauty device has surpassed 10,000 users, and the professional equipment has received Class II medical device certification, with over 100 private institutions procuring it [4]. Profit Forecast and Investment Recommendations - The company is positioned as a global leader in vapor technology solutions, with increasing competitive advantages. The report anticipates significant contributions from HNB business starting in 2026, with adjusted net profit forecasts for 2025-2027 set at 14.72 billion, 19.79 billion, and 26.63 billion yuan, respectively, reflecting year-on-year growth rates of 34.40% and 34.60% for 2026 and 2027 [5].

Investment Rating - The report maintains a "Buy" rating for the company, expecting a relative return of over 20% within the next six months [5][14]. Core Viewpoints - The company is expected to benefit from the tightening global regulations on vaping products, particularly in the e-cigarette sector, and anticipates significant growth in its Heat-Not-Burn (HNB) business [2][4]. - The company reported a revenue of 6.013 billion yuan for the first half of 2025, representing an 18% year-on-year increase, driven by growth in its proprietary brand and enterprise client businesses [2][4]. - The decline in net profit, projected between 443 million to 541 million yuan, is attributed to increased non-cash expenses related to stock options and a rise in marketing and legal costs [1][4]. Summary by Sections Financial Performance - For the first half of 2025, the company expects revenue of 60.13 billion yuan, up 18% year-on-year, while net profit is projected to decline by 21% to 35% [1][2]. - Adjusted net profit, excluding non-cash stock-based payments, is estimated to be between 688 million to 787 million yuan, reflecting a year-on-year change of -9% to +4% [1]. Market Dynamics - The UK market is undergoing significant changes due to a ban on disposable e-cigarettes, which is expected to shift consumer demand towards reusable products [2]. - In the US, regulatory actions against illegal e-cigarettes have intensified, with over 135 million USD worth of illegal products seized since 2023, indicating a tightening market environment [2]. Growth Opportunities - The HNB business is anticipated to become a significant growth driver starting in 2026, contributing notably to revenue and profit [4]. - The company is enhancing its market presence, particularly in overseas markets, which is expected to sustain growth in its proprietary brand and enterprise client segments [2][4].